INTRODUCTION: Two-step and three-step pretargeting systems utilizing biotinylated prostate tumor-homing bacteriophage (phage) and (111)In-radiolabeled streptavidin or biotin were developed for use in cancer radioimaging. The in vivo selected prostate carcinoma-specific phage (G1) displaying up to five copies of the peptide IAGLATPGWSHWLAL was the focus of the present study. METHODS: The ability of G1 phage to extravasate and target prostate tumor cells was investigated using immunohistochemistry. G1 phages were biotinylated, streptavidin was conjugated to diethylenetriaminepentaacetic acid (DTPA) and biotin was conjugated to 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA). Biodistribution studies and single-photon emission computed tomography (SPECT)/CT imaging of xenografted PC-3 tumors via two-step pretargeted (111)In-labeled streptavidin and three-step pretargeted (111)In-labeled biotin were performed in SCID mice to determine the optimal pretargeting method. RESULTS: The ability of G1 phage to extravasate the vasculature and bind directly to human PC-3 prostate carcinoma tumor cells in vivo was demonstrated via immunocytochemical analysis. Comparative biodistribution studies of the two-step and three-step pretargeting strategies indicated increased PC-3 human prostate carcinoma tumor uptake in SCID mice of 4.34+/-0.26 %ID g(-1) at 0.5 h postinjection of (111)In-radiolabeled biotin (utilized in a three-step protocol) compared to 0.67+/-0.06 %ID g(-1) at 24 h postinjection of (111)In radiolabeled streptavidin (employed in a two-step protocol). In vivo SPECT/CT imaging of xenografted PC-3 tumors in SCID mice with the three-step pretargeting method was superior to that of the two-step pretargeting method, and, importantly, blocking studies demonstrated specificity of tumor uptake of (111)In-labeled biotin in the three-step pretargeting scheme. CONCLUSION: This study demonstrates the use of multivalent bifunctional phage in a three-step pretargeting system for prostate cancer radioimaging.
INTRODUCTION: Two-step and three-step pretargeting systems utilizing biotinylated prostate tumor-homing bacteriophage (phage) and (111)In-radiolabeled streptavidin or biotin were developed for use in cancer radioimaging. The in vivo selected prostate carcinoma-specific phage (G1) displaying up to five copies of the peptide IAGLATPGWSHWLAL was the focus of the present study. METHODS: The ability of G1 phage to extravasate and target prostate tumor cells was investigated using immunohistochemistry. G1 phages were biotinylated, streptavidin was conjugated to diethylenetriaminepentaacetic acid (DTPA) and biotin was conjugated to 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA). Biodistribution studies and single-photon emission computed tomography (SPECT)/CT imaging of xenografted PC-3tumors via two-step pretargeted (111)In-labeled streptavidin and three-step pretargeted (111)In-labeled biotin were performed in SCIDmice to determine the optimal pretargeting method. RESULTS: The ability of G1 phage to extravasate the vasculature and bind directly to humanPC-3prostate carcinoma tumor cells in vivo was demonstrated via immunocytochemical analysis. Comparative biodistribution studies of the two-step and three-step pretargeting strategies indicated increased PC-3human prostate carcinomatumor uptake in SCIDmice of 4.34+/-0.26 %ID g(-1) at 0.5 h postinjection of (111)In-radiolabeled biotin (utilized in a three-step protocol) compared to 0.67+/-0.06 %ID g(-1) at 24 h postinjection of (111)In radiolabeled streptavidin (employed in a two-step protocol). In vivo SPECT/CT imaging of xenografted PC-3tumors in SCIDmice with the three-step pretargeting method was superior to that of the two-step pretargeting method, and, importantly, blocking studies demonstrated specificity of tumor uptake of (111)In-labeled biotin in the three-step pretargeting scheme. CONCLUSION: This study demonstrates the use of multivalent bifunctional phage in a three-step pretargeting system for prostate cancer radioimaging.
Authors: Andres Forero-Torres; Sui Shen; Hazel Breitz; Robert B Sims; Don B Axworthy; M B Khazaeli; Kuang-Ho Chen; Ivor Percent; Stephen Besh; Albert F LoBuglio; Ruby F Meredith Journal: Cancer Biother Radiopharm Date: 2005-08 Impact factor: 3.099
Authors: Emmanuelle di Tomaso; Diane Capen; Amy Haskell; Janet Hart; James J Logie; Rakesh K Jain; Donald M McDonald; Rosemary Jones; Lance L Munn Journal: Cancer Res Date: 2005-07-01 Impact factor: 12.701
Authors: D S Wilbur; D K Hamlin; K R Buhler; P M Pathare; R L Vessella; P S Stayton; R To Journal: Bioconjug Chem Date: 1998 May-Jun Impact factor: 4.774
Authors: Kevin J Hamblett; Oliver W Press; Damon L Meyer; Don K Hamlin; Don Axworthy; D Scott Wilbur; Patrick S Stayton Journal: Bioconjug Chem Date: 2005 Jan-Feb Impact factor: 4.774
Authors: Xiaoyuan Chen; Eric Sievers; Yingping Hou; Ryan Park; Michel Tohme; Robert Bart; Ross Bremner; James R Bading; Peter S Conti Journal: Neoplasia Date: 2005-03 Impact factor: 5.715
Authors: Jasmina Lovrić; Hassan S Bazzi; Yan Cuie; Genevieve R A Fortin; Françoise M Winnik; Dusica Maysinger Journal: J Mol Med (Berl) Date: 2005-02-02 Impact factor: 4.599
Authors: Jessica R Newton-Northup; Marie T Dickerson; Senthil R Kumar; George P Smith; Thomas P Quinn; Susan L Deutscher Journal: Mol Imaging Biol Date: 2014-12 Impact factor: 3.488